The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia

被引：0

作者：

Erdmann, R. ^{[1
,2
]}

Jorgensen, H. ^{[3
]}

Ben-Batalla, I. ^{[1
,2
]}

Kruse, N. ^{[1
,2
]}

Micklem, D. ^{[4
]}

von Amsberg, G. ^{[1
]}

Schafhausen, P. ^{[1
]}

Schultze, A. ^{[1
]}

Wroblewski, M. ^{[1
,2
]}

Binder, M. ^{[1
]}

Cubas-Cordova, M. ^{[1
,2
]}

Hadlich, T. ^{[1
]}

Janing, M. ^{[1
,2
]}

Sawall, S. ^{[1
,2
]}

Witzke, V. ^{[1
,2
]}

Lorens, J. ^{[4
]}

Allan, E. ^{[3
]}

Mukherjee, L. ^{[3
]}

Morrison, H. ^{[3
]}

Cassells, J. ^{[3
]}

Koerger, N. ^{[5
]}

Lorens, J. B. ^{[6
]}

Clark, R. ^{[7
]}

Koschmieder, S. ^{[8
]}

Vandenberghe, P. ^{[9
]}

Bruemmendorf, T. ^{[8
]}

Hochhaus, A. ^{[10
]}

Carmeliet, P. ^{[11
]}

Holyoake, T. ^{[3
]}

Pantel, K. ^{[2
]}

Bokemeyer, C. ^{[1
,12
]}

Loges, S. ^{[1
,2
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Med Clin 2, Hamburg, Germany

[2] Dept Tumor Biol, Hamburg, Germany

[3] Univ Glasgow, Paul OGorman Leukemia Res Ctr, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland

[4] BerGenBio AS, Jonas Lies, Bergen, Norway

[5] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Bone Marrow Transplantat Unit, Hamburg, Germany

[6] Univ Bergen, Dept Biomed, Bergen, Norway

[7] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England

[8] Univ Klinikum RWTH Aachen, Aachen, Germany

[9] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium

[10] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[11] VIB, Lab Angiogenesis & Neurovasc Link, Vesalius Res Ctr, Leuven, Belgium

[12] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol & Oncol, Hamburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V935

引用

页码：309 / 309

页数：1

共 50 条

[1] BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
Erdmann, Robert
Jorgensen, Heather
Ben-Batalla, Isabel
Kruse, Nils
Micklem, David
von Amsberg, Gunhild
Schafhausen, Philippe
Schultze, Alexander
Wroblewski, Mark
Binder, Mascha
Cubas-Cordova, Miguel
Hadlich, Tobias
Janning, Melanie
Sawall, Stefanie
Gensch, Victoria
Allan, Elaine K.
Mukherjee, Leena
Morrison, Heather
Cassells, Jennifer
Kroeger, Nicolaus
Lorens, James
Clark, Richard E.
Koschmieder, Steffen
Vandenberghe, Peter
Bruemmendorf, Tim H.
Hochhaus, Andreas
Carmeliet, Peter
Holyoake, Tessa L.
Pantel, Klaus
Bokemeyer, Carsten
Loges, Sonja
BLOOD, 2014, 124 (21)
[2] SELECTIVE SMALL MOLECULE AXL INHIBITOR BGB324 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
Gausdal, G.
Wnuk-Lipinska, K.
Milde, E.
Sandal, T.
Hellesoy, M.
Ahmed, L.
Haugen, H.
Loges, S.
Micklem, D.
Lorens, J.
Zhou, L.
HAEMATOLOGICA, 2013, 98 : 690 - 690
[3] Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia
Erdmann, Robert
Jorgensen, Heather
Schultze, Alexander
von Amsberg, Gunhild
Ben-Battala, Isabel
Wroblewski, Mark
Cordova, Miguel Cubes
Sawall, Stefanie
Witzke, Victoria
Allan, Elaine K.
Mukherjee, Leena
Morrison, Heather
Cassels, Jennifer
Schafhausen, Philippe
Kroeger, Nicolaus
Lorens, James
Clark, Richard E.
Vandenberghe, Peter
Bruemmendorf, Tim H.
Hochhaus, Andreas
Carmeliet, Peter
Pantel, Klaus
Bokemeyer, Carsten
Holyoake, Tessa L.
Loges, Sonja
BLOOD, 2013, 122 (21)
[4] Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben-Batalla, Isabel
Erdmann, Robert
Jorgensen, Heather
Mitchell, Rebecca
Ernst, Thomas
Von Amsberg, Gunhild
Schafhausen, Philippe
Velthaus, Janna L.
Rankin, Stephen
Clark, Richard E.
Koschmieder, Steffen
Schultze, Alexander
Mitra, Subir
Vandenberghe, Peter
Brummendorf, Tim H.
Carmeliet, Peter
Hochhaus, Andreas
Pantel, Klaus
Bokemeyer, Carsten
Helgason, G. Vignir
Holyoake, Tessa L.
Loges, Sonja
CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2289 - 2300
[5] Small molecule Axl inhibitor BGB324 inhibits primary chronic phase chronic myeloid leukaemia (CML) cell function and viability
Mukherjee, L.
Rankin, S.
Laird, A.
Hsieh, Y-C
Hopcroft, L. E. M.
Allan, E. K.
Ben Batalla, I.
Micklem, D.
Holyoake, T. L.
Loges, S.
Jorgensen, H. G.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 119 - 119
[6] Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
Quintas-Cardama, Alfonso
Cortes, Jorge
CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4392 - 4399
[7] Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
Gupta, Pranav
Zhang, Guan-Nan
Barbuti, Anna Maria
Zhang, Xin
Karadkhelkar, Nishant
Zhou, Jingfeng
Ding, Ke
Pan, Jingxuan
Yoganathan, Sabesan
Yang, Dong-Hua
Chen, Zhe-Sheng
CANCER LETTERS, 2020, 472 : 132 - 141
[8] Targeting the PTP1B-Bcr-Abl1 interaction for the degradation of T315I mutant Bcr-Abl1 in chronic myeloid leukemia
Elgehama, Ahmed
Wang, Yixuan
Yu, Ying
Zhou, Lin
Chen, Zhixiu
Wang, Liwei
Sun, Lijun
Gao, Jian
Yu, Biao
Shen, Yan
Xu, Qiang
CANCER SCIENCE, 2023, 114 (01) : 247 - 258
[9] Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
Rea, Delphine
Lang, Fabian
Kim, Dong-Wook
Cortes, Jorge E.
Hughes, Timothy P.
Minami, Hironobu
Breccia, Massimo
Deangelo, Daniel J.
Hochhaus, Andreas
Talpaz, Moshe
Goh, Yeow Tee
le Coutre, Philipp
Deininger, Michael W.
Etienne, Gabriel
Sondhi, Manu
Mishra, Kaushal
Aimone, Paola
Ng-Sikorski, Janet
Mauro, Michael J.
BLOOD, 2018, 132
[10] Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Yanli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Zeng, Shan
Men, Lichuang
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Lu, Ming
Wang, Hengbang
Ji, Jiao
Yue, Changai
Yang, Dajun
Zhai, Yifan
BLOOD, 2020, 136

← 1 2 3 4 5 →